Hims & Hers Health, Inc. Class A Common Stock (HIMS)
59.69
-3.07 (-4.90%)
NYSE · Last Trade: Oct 16th, 2:02 PM EDT
Detailed Quote
Previous Close
62.76
Open
62.12
Bid
59.65
Ask
59.73
Day's Range
58.50 - 63.63
52 Week Range
18.33 - 72.98
Volume
25,470,773
Market Cap
11.46B
PE Ratio (TTM)
75.55
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
29,289,351
Chart
About Hims & Hers Health, Inc. Class A Common Stock (HIMS)
Hims & Hers Health Inc is a telehealth company that focuses on providing accessible and affordable healthcare solutions for a variety of needs, particularly focusing on personal wellness and self-care. The company offers a range of products and services, including prescription medications for conditions such as hair loss, erectile dysfunction, and skincare, as well as wellness supplements and telemedicine consultations. By leveraging technology, Hims & Hers aims to simplify the healthcare experience, making it more convenient for consumers to receive treatment and advice from licensed professionals without the barriers typically associated with traditional healthcare delivery. Read More
The rally followed BofA Securities’ announcement that the new menopause and perimenopause service represents a multi-billion-dollar market opportunity for HIMS, supporting revenue diversification.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 5.7% in the afternoon session after the company announced the launch of perimenopause and menopause treatment options on its platform. This expansion into women's health offered customers access to personalized treatment plans and prescription medications, including estradiol and progesterone. The treatments were made available in various forms such as pills, patches, and creams. The move was seen as a significant step for the company, which was reportedly on a path to achieve over $1 billion in annual revenue by 2026. By adding these hormone-replacement therapies, Hims & Hers broadened its services for its large subscriber base.
Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Wednesday following the company's launch of a new menopause and perimenopause care specialty on its Hers platform.
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the launch of a new specialty in women’s health, offering access to affordable treatment plans built specifically for women experiencing perimenopause and menopause. Starting today, women can work with a provider on the platform to access treatment plans tailored to their health history and personal preferences.
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced that it will report third quarter 2025 financial results after the market closes on Monday, November 3, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue forecast.
Hims & Hers Health, Inc. (NYSE: HIMS) today published a new white paper - Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety - detailing how rigorous standards, continuous monitoring, and customer-centered design are shaping the future of safe and effective telehealth.
HIMS stock shows strong technical momentum and a consolidation pattern, suggesting a potential breakout. The setup offers a clear risk/reward profile for technical traders.
Hims & Hers (HIMS) is a high-growth momentum stock with strong earnings and a positive technical breakout setup, offering a compelling opportunity for investors.
A number of stocks jumped in the afternoon session after news of a new government prescription drug policy and a landmark deal with Pfizer eased investor concerns over stricter pricing regulations.
